## Susanne Sebens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/756993/publications.pdf

Version: 2024-02-01

45 papers 1,526 citations

20 h-index 330143 37 g-index

46 all docs

46 docs citations

46 times ranked 2701 citing authors

#	Article	IF	CITATIONS
1	Tumorâ€associated macrophages exhibit pro―and antiâ€inflammatory properties by which they impact on pancreatic tumorigenesis. International Journal of Cancer, 2014, 135, 843-861.	5.1	216
2	Novel Bispecific Antibodies Increase $\hat{I}^3\hat{I}$ T-Cell Cytotoxicity against Pancreatic Cancer Cells. Cancer Research, 2014, 74, 1349-1360.	0.9	133
3	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing Î <sup>3</sup> δT Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Frontiers in Immunology, 2018, 9, 814.	4.8	84
4	Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. Cancer Letters, 2018, 415, 129-150.	7.2	80
5	Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2014, 9, e94357.	2.5	70
6	Identification and characterization of two functional variants in the human longevity gene FOXO3. Nature Communications, 2017, 8, 2063.	12.8	69
7	Cytoprotection & amp; Idquo; gone astray & amp; rsquo; & amp; rsquo;: Nrf2 and its role in cancer. OncoTargets and Therapy, 2014, 7, 1497.	2.0	57
8	The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?. Current Pharmaceutical Biotechnology, 2012, 13, 2259-2272.	1.6	56
9	γδT cell activation by bispecific antibodies. Cellular Immunology, 2015, 296, 41-49.	3.0	54
10	Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Letters, 2012, 319, 66-82.	7.2	49
11	The Crosstalk between Nrf2 and TGF- $\hat{l}^21$ in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells. PLoS ONE, 2015, 10, e0132978.	2.5	48
12	Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against $\hat{I}^3\hat{I}$ T cell cytotoxicity. Oncolmmunology, 2015, 4, e988460.	4.6	41
13	Inflammatory Macrophages Induce Nrf2 Transcription Factor-dependent Proteasome Activity in Colonic NCM460 Cells and Thereby Confer Anti-apoptotic Protection. Journal of Biological Chemistry, 2011, 286, 40911-40921.	3.4	39
14	Seasonal Variations in the Metabolome and Bioactivity Profile of Fucus vesiculosus Extracted by an Optimised, Pressurised Liquid Extraction Protocol. Marine Drugs, 2018, 16, 503.	4.6	39
15	The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. Neurochemistry International, 2012, 61, 1183-1191.	3.8	37
16	Monitoring Circulating γδT Cells in Cancer Patients to Optimize γδT Cell-Based Immunotherapy. Frontiers in Immunology, 2014, 5, 643.	4.8	34
17	L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Molecular Oncology, 2014, 8, 982-997.	4.6	34
18	The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Oncolmmunology, 2018, 7, e1368603.	4.6	33

#	Article	IF	CITATIONS
19	Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Pancreatology, 2016, 16, 1069-1079.	1.1	28
20	Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreatic ductal epithelial cells. Cancer Letters, 2019, 453, 95-106.	7.2	26
21	Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells. Cancers, 2020, 12, 581.	3.7	22
22	Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clinical and Experimental Metastasis, 2014, 31, 87-100.	3.3	20
23	The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers, 2021, 13, 4932.	3.7	19
24	Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. Oncotarget, 2018, 9, 31771-31786.	1.8	19
25	Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis, 2012, 33, 84-93.	2.8	18
26	The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF- $\hat{l}^21$ mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF- $\hat{l}^21$ . BMC Cancer, 2016, 16, 155.	2.6	17
27	Recent insights into the role of <scp>L1CAM</scp> in cancer initiation and progression. International Journal of Cancer, 2020, 147, 3292-3296.	5.1	17
28	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses $\hat{I}^3\hat{I}$ T Cell Proliferation but Not Their Cytotoxicity. Frontiers in Immunology, 2020, 11, 1328.	4.8	16
29	Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers, 2021, 13, 4235.	3.7	16
30	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. PLoS ONE, 2020, 15, e0239369.	2.5	14
31	Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD). Current Pharmaceutical Design, 2020, 26, 3840-3846.	1.9	14
32	The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Cancers, 2019, 11, 745.	3.7	12
33	Pitfalls in the characterization of circulating and tissue-resident human γδT cells. Journal of Leukocyte Biology, 2020, 107, 1097-1105.	3.3	12
34	Response to:  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma'. Gut, 2019, 68, 179-180.	12.1	11
35	Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Medical Sciences (Basel,) Tj ETQq1 1	0.7 <b>2.9</b> 314	rgBō/Overlo
36	Multimodal Targeted Nanoparticle-Based Delivery System for Pancreatic Tumor Imaging in Cellular and Animal Models. Current Pharmaceutical Design, 2022, 28, 313-323.	1.9	10

#	Article	IF	Citations
37	Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells. International Journal of Molecular Sciences, 2021, 22, 5086.	4.1	8
38	Utilizing ICG Spectroscopical Properties for Real-Time Nanoparticle Release Quantification In vitro and In vivo in Imaging Setups. Current Pharmaceutical Design, 2020, 26, 3828-3833.	1.9	8
39	The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant î"Zip2. Oncogene, 2019, 38, 1461-1476.	5.9	7
40	The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 740606.	2.8	6
41	Inflammation Associated Pancreatic Tumorigenesis: Upregulation of Succinate Dehydrogenase (Subunit B) Reduces Cell Growth of Pancreatic Ductal Epithelial Cells. Cancers, 2020, 12, 42.	3.7	5
42	Utilizing Sphingomyelinase Sensitizing Liposomes in Imaging Intestinal Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis. Biomedicines, 2022, 10, 413.	3.2	5
43	Plant-derived saccharides and their inhibitory potential on metastasis associated cellular processes of pancreatic ductal adenocarcinoma cells. Carbohydrate Research, 2020, 490, 107903.	2.3	4
44	Insulin Receptor in Pancreatic Cancerâ€"Crown Witness in Cross Examination. Cancers, 2021, 13, 4988.	3.7	4
45	Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts. Communications Biology, 2022, 5, 59.	4.4	3